Patents by Inventor Sophie Marie Jeanne Valentine Germain

Sophie Marie Jeanne Valentine Germain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10130694
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminum-free adjuvant.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 20, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique Boutriau, Sophie Marie Jeanne Valentine Germain, Hugues Wallemacq
  • Publication number: 20170340719
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminium-free adjuvant.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique BOUTRIAU, Sophie Marie Jeanne Valentine GERMAIN, Hugues WALLEMACQ
  • Patent number: 9694064
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminum-free adjuvant.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 4, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique Boutriau, Sophie Marie Jeanne Valentine Germain, Hugues Wallemacq
  • Publication number: 20150313984
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C.difficile) polypeptide and an aluminium-free adjuvant.
    Type: Application
    Filed: December 3, 2013
    Publication date: November 5, 2015
    Inventors: Dominique BOUTRIAU, Sophie Marie Jeanne Valentine GERMAIN, Hugues WALLEMACQ
  • Patent number: 8715687
    Abstract: The present invention relates to ClfA polypeptides wherein amino acid Y474 or an amino acid adjacent to Y474 is mutated such that fibrinogen binding activity is decreased compared to an equivalent ClfA polypeptide without mutation of Y474 or an amino acid adjacent to Y474 as well as immunogenic compositions, vaccines, processes and uses of such mutated ClfA polypeptides.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: May 6, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy Dequesne, Sophie Marie Jeanne Valentine Germain
  • Publication number: 20120189650
    Abstract: The present invention relates to ClfA polypeptides wherein amino acid Y474 or an amino acid adjacent to Y474 is mutated such that fibrinogen binding activity is decreased compared to an equivalent ClfA polypeptide without mutation of Y474 or an amino acid adjacent to Y474 as well as immunogenic compositions, vaccines, processes and uses of such mutated ClfA polypeptides.
    Type: Application
    Filed: August 3, 2010
    Publication date: July 26, 2012
    Inventors: Guy Dequesne, Sophie Marie Jeanne Valentine Germain
  • Publication number: 20120141523
    Abstract: The present application relates to an immunogenic composition comprising a fragment of a staphylococcal Isd protein such as IsdA, IsdB, IsdC or IsdH which comprises a NEAT domain. Fusion proteins comprising a NEAT domain of a first staphylococcal Isd protein and a NEAT domain from a second Isd protein are also disclosed as well as fusion proteins comprising a NEAT domain of a staphylococcal Isd protein involved in an iron/heme uptake system and a ligand binding domain of a staphylococcal extracellular component binding protein, for example ClfA, ClfB, SdrC, SdrD or SdrE.
    Type: Application
    Filed: August 3, 2010
    Publication date: June 7, 2012
    Inventors: Cindy Castado, Sophie Marie Jeanne Valentine Germain, Melanie Gilbert